Pharma News for the week of May 7, 2020


Drugmakers, medical research and healthcare organizations involved with the response to the Covid-19 pandemic have been victims of state-backed hacking campaigns, cybersecurity bodies in the U.S. and U.K. have warned. (Medcitynews)

In particular, Bright claimed his involuntary transfer to a reduced role at the National Institutes of Health was retaliation for his pushback against plans by the Trump administration to widely distribute unproven drugs like hydroxychloroquine to treat COVID-19. (Biopharmadrive)

The global health emergency has shut down scientific research labs across the country in a crisis that has left some scientists scrambling to save their work — and has left others grieving the loss of experiments they had dedicated months or even years to carrying out. Many are grappling with an overwhelming sense of uncertainty about how they’ll continue their work. (Statnews)

Several of the U.S.’s biggest for-profit insurers will give money back to customers and cut upfront costs for care and prescriptions, after they got an unexpected windfall because patients delayed normal medical services during the pandemic. (Fortune)

A patient hospitalized with flu-like symptoms at the end of December in France turned out to have had Covid-19, a finding that suggests the new coronavirus was spreading there at least a month earlier than official records show. (Fortune)